


REQUEST FOR ACCESS TO AN APPLICATION UNDER 37 CFR 1.14(e)



In re Application of

Application Number

99/256388

Filed

2/24/99

Art Unit

G. 1600

Examiner

Paper No.

#10

Assistant Commissioner for Patents
Washington, DC 20231

1. ☒ I hereby request access under 37 CFR 1.14(e)(2) to the application file record of the above-identified ABANDONED Application, which is not within the file jacket of a pending Continued Prosecution Application (CPA) (37 CFR 1.53(d)) and is: (CHECK ONE)

☒ (A) referred to in:

United States Patent Application Publication No. _____, page _____, line _____,

United States Patent Number 6015557, column _____, line _____, or

an International Application which was filed on or after November 29, 2000 and which

designates the United States, WIPO Pub. No. _____, page _____, line _____.

☐ (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11(b) or

1.14(e)(2)(i), i.e., Application No. _____, paper No. _____, page _____, line _____.

2. ☐ I hereby request access under 37 CFR 1.14(e)(1) to an application in which the applicant has filed an authorization to lay open the complete application to the public.

Kien VJ

Signature

KIEN VJ

Typed or printed name

7/30/03

RECEIVED

FOR PTO USE ONLY

AUG 04 2003

Approved by: _____

File Information Unit

Unit: _____



US006015557A

United States Patent [19]

Tobinick et al.

[11] **Patent Number:** **6,015,557**[45] **Date of Patent:** **Jan. 18, 2000**

[54] **TUMOR NECROSIS FACTOR ANTAGONISTS
FOR THE TREATMENT OF
NEUROLOGICAL DISORDERS**

5,656,272 8/1997 Le et al. .

5,795,967 8/1998 Aggarwal et al. .

[76] **Inventors:** Edward L. Tobinick; Arthur Jerome
Tobinick, both of 100 UCLA Medical
Plz., Suite 205, Los Angeles, Calif.
90024-6903

Primary Examiner—William R. A. Jarvis*Attorney, Agent, or Firm*—Ezra Sutton[21] **Appl. No.:** **09/275,070**[22] **Filed:** **Mar. 23, 1999****Related U.S. Application Data**[63] Continuation-in-part of application No. 09/256,388, Feb. 24, 1999, abandoned.[51] **Int. Cl.⁷** A61K 39/395; A61K 31/495;
A61K 31/50; A61K 31/42[52] **U.S. Cl.** 424/134.1; 514/249; 514/378[58] **Field of Search** 424/134.1; 514/249,
514/378[56] **References Cited****U.S. PATENT DOCUMENTS**

5,605,690 2/1997 Jacobs et al. .

[57] **ABSTRACT**

A method for inhibiting the action of TNF for treating neurological conditions in a human by administering a TNF antagonist for reducing damage to neuronal tissue or for modulating the immune response affecting neuronal tissue of the human. The TNF antagonist administered is selected from the group consisting of etanercept and infliximab. The TNF antagonist is administered subcutaneously, intravenously, intrathecally, or intramuscularly.

Methotrexate or Leflunomide may be administered concurrently with the TNF antagonist for demyelinating diseases and certain other neurological disorders.

47 Claims, No Drawings